Monday 12 January 2015

Canada's Tekmira to buy U.S.-based OnCore Biopharma, focus on HBV treatment

(Reuters) - Canada's Tekmira Pharmaceuticals Corp agreed to buy Pennsylvania-based OnCore Biopharma Inc to focus on developing hepatitis B virus treatment by combining multiple therapeutic methods. The implied market value of the merged company is about $750 million, based on Tekmira stock's closing price of $15.70 on the Nasdaq on Jan. 9, the companies said in a statement. OnCore will become a wholly-owned subsidiary of Tekmira and upon closing of the deal, OnCore shareholders will hold about 50 percent of the total outstanding shares of Tekmira. ... via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment